BlackThorn Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.blackthornrx.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
- Conditions
- Motor DisorderParkinson Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03608371
- Locations
- 🇺🇸
BlackThorn Investigator Site, Dallas, Texas, United States
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo oral capsule(s)
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT03193398
- Locations
- 🇺🇸
United States, Memphis, Tennessee, United States
🇺🇸United States, Florida, Orlando, Florida, United States
A Study of LY2940094 in Participants With Alcohol Dependency
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT01798303
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01724112
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- BlackThorn Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01404091
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada
- Prev
- 1
- 2
- Next